Diamond Hill Capital Management Inc. Sells 49,320 Shares of uniQure N.V. $QURE

Diamond Hill Capital Management Inc. lessened its stake in shares of uniQure N.V. (NASDAQ:QURE) by 59.7% during the third quarter, Holdings Channel.com reports. The fund owned 33,333 shares of the biotechnology company’s stock after selling 49,320 shares during the period. Diamond Hill Capital Management Inc.’s holdings in uniQure were worth $1,946,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of the stock. Private Trust Co. NA acquired a new stake in shares of uniQure during the 3rd quarter worth $28,000. Jones Financial Companies Lllp grew its stake in uniQure by 509.0% during the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after buying an additional 509 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in uniQure by 358.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock valued at $99,000 after buying an additional 5,538 shares during the period. KLP Kapitalforvaltning AS acquired a new position in shares of uniQure in the 2nd quarter valued at approximately $117,000. Finally, Teacher Retirement System of Texas acquired a new position in shares of uniQure in the 2nd quarter valued at approximately $151,000. 78.83% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, Director Jack Kaye sold 6,390 shares of uniQure stock in a transaction on Friday, January 9th. The shares were sold at an average price of $27.28, for a total transaction of $174,319.20. Following the transaction, the director owned 20,439 shares in the company, valued at approximately $557,575.92. The trade was a 23.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Robert Gut sold 25,613 shares of the business’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $24.62, for a total transaction of $630,592.06. Following the completion of the sale, the director directly owned 32,342 shares in the company, valued at approximately $796,260.04. This represents a 44.19% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 4.79% of the company’s stock.

uniQure Price Performance

uniQure stock opened at $25.65 on Monday. The stock has a 50-day moving average price of $23.44 and a two-hundred day moving average price of $28.92. uniQure N.V. has a 12 month low of $7.76 and a 12 month high of $71.50. The company has a market capitalization of $1.60 billion, a PE ratio of -5.84 and a beta of 0.66. The company has a current ratio of 7.12, a quick ratio of 7.12 and a debt-to-equity ratio of 0.23.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.53). The firm had revenue of $3.70 million during the quarter, compared to analyst estimates of $4.46 million. uniQure had a negative net margin of 1,492.90% and a negative return on equity of 373.73%. Analysts expect that uniQure N.V. will post -3.75 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on QURE shares. Benchmark reissued a “buy” rating on shares of uniQure in a research note on Tuesday, November 4th. The Goldman Sachs Group reduced their target price on uniQure from $56.00 to $38.00 and set a “neutral” rating on the stock in a report on Tuesday, November 4th. Chardan Capital reissued a “buy” rating and set a $53.00 price target on shares of uniQure in a report on Thursday, December 4th. HC Wainwright reduced their price objective on uniQure from $110.00 to $70.00 and set a “buy” rating on the stock in a research note on Tuesday, November 4th. Finally, Wells Fargo & Company decreased their target price on uniQure from $80.00 to $60.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 12th. Ten research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $58.33.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.